Use of oral contraceptives and endometrial cancer risk (Sweden)

Cancer Causes and Control

Volumn 10, Issue 4, 1999, Pages 277-284

  Weiderpass, Elisabete ^a,d   Adami, Hans Olov ^a,b   Baron, John A ^c   Magnusson, Cecilia ^a   Lindgren, Anders ^d   Persson, Ingemar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b HARVARD CENTER FOR CANCER PREVENTION   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d FALUN HOSPITAL   (Sweden)

Author keywords

Combined oral contraceptives; Endometrial neoplasms; Sweden

Indexed keywords

DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; LEVONORGESTREL; LYNESTEROL; MEDROXYPROGESTERONE ACETATE; MESTRANOL; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; DRUG USE; ENDOMETRIUM CANCER; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SWEDEN;

AGE DISTRIBUTION; AGED; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, COMBINED; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; QUESTIONNAIRES; RISK FACTORS; SWEDEN;

EID: 0032767421     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008945721786     Document Type: Article

References (29)

1. 1. International Agency for Research on Cancer (1999) Some Hormones, Postmenopausal Hormone Therapy, and Hormonal Contraception. Lyon: IARC Monograph on the evaluation of carcinogenic risks to humans, vol. 72 (in press).
2. Breslow NE, Day NE (1980) Statistical Methods in Cancer Research. vol. 1: The Analysis of Case-Control Studies. Lyon: International Agency for Research on Cancer, pp. 192-246.
3. Weiderpass E, Baron JA, Adami HO, et al. (1999) Low potency estrogen formulations and risk for endometrial cancer. Lancet (in press).
4. Gray LA Sr, Christopherson WM, Hoover RN (1977) Estrogens and endometrial carcinoma. Obstet Gynecol 49: 385-389.
5. Weiss NS, Sayvetz TA (1980) Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med 302: 551-554.
6. Kaufman DW, Shapiro S, Slone D, et al. (1980) Decreased risk of endometrial cancer among oral contraceptive users. N Engl J Med 303: 1045-1048.
7. Hulka BS, Chambless LE, Kaufman DC, Fowler WC Jr, Greenberg BG (1982) Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA 247: 475-477.
8. Kelsey JL, Livolsi VA, Holford TR, et al. (1982) A case control study of cancer of the endometrium. Am J Epidemiol 116: 333-342.
9. La Vecchia C, Francheschi S, Decarli A, Gallus G, Tognoni G (1984) Risk factors for endometrial cancer in different ages. J Natl Cancer Inst 73: 667-671.
10. La Vecchia C, Decarli A, Fasoli M, et al. ( 1986) Oral contraceptives and cancers of the breast and of the female genital tract: interim results from a case-control study. Br J Cancer 54: 311-317.
11. Pettersson B, Adami H-O, Bergström R, Johansson EDB (1986) Menstruation span a time-limited risk factor for endometrial cancer. Acta Obstet Gynecol Scand 65: 247-255.
12. 12. Centers for Disease Control and the National Institute of Child Health and Human Development (1987) The Cancer and Steroid Hormone Study. Combination oral contraceptive use and the risk of endometrial cancer. JAMA 257: 796-800.
13. 13. World Health Organization (WHO) Collaborative Study of Neoplasia and Steroid Contraceptives (1988) Endometrial cancer and combined oral contraceptives, Int J Epidemiol 17: 263-269.
14. Koumantaki Y, Tzonou A, Koumantakis E, Kaklamani E, Aravantinos D, Trichopoulos D (1989) A case-control study of cancer of endometrium in Athens. Int J Cancer 43: 795-799.
15. Levi F, La Vecchia C, Gulie C, et al. (1991) Oral contraceptives and the risk of endometrial cancer. Cancer Causes Control 2: 99-101.
16. Rosenblatt KA, Thomas DB (1991) The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial cancer. Int J Cancer 49: 870-874.
17. Shu XO, Brinton LA, Zheng W, Gao YT, Fan J, Fraumeni JF Jr (1991) A population-based case-control study of endometrial cancer in Shanghai, China. Int J Cancer 19: 38-43.
18. Jick SS, Walker AM, Jick H (1993) Oral contraceptives and endometrial cancer. Obstet Gynecol 82: 931-935.
19. Stanford JL, Brinton LA, Berman ML, et al. (1993) Oral contraceptives and endometrial cancer: do other risk factors modify this association? Int J Cancer 54: 243-248.
20. Voigt LF, Deng Q, Weiss NS (1994) Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer. Cancer Causes Control 5: 227-233.
21. Vessey MP, Painter R (1995) Endometrial and ovarian cancer and oral contraceptives findings in a large cohort study. Br J Cancer 71: 1340-1332.
22. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A (1983) The epidemiology of endometrial cancer in young women. Br J Cancer 47: 749-756.
23. Key TJA, Beral V (1992) Sex hormones and cancer. In: Vainio H, Magee PN, McGregor DB, Me Michel AJ, eds. Mechanisms of Carcinogenesis in Risk Identification. Lyon: International Agency for Research on Cancer, pp. 225-269.
24. Gurpide E, (1991) Endometrial cancer: biochemical and clinical correlates. J Natl Cancer Inst 83: 405-416.
25. Hsueh AJ, Peck EJ Jr, Clark JH (1975) Progesterone antgonism of the oestrogen receptor and estrogen-induced uterine growth. Nature 254: 337-339.
26. Tseng L, Gurpide E (1975) Effects of progestins on estradiol receptor levels in human endometrium. J Clin Endocrinolol Metab 41: 402-404.
27. Graham JD, Clarke CL (1997) Physiological action of progester-one in target tissues. Endocrinol Rev 18: 502-519.
28. Grady D, Gebretsadik T, Ernster V, Pettiti D (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85: 304-313.
29. Beresford SA, Weiss NS, Voigt LF, McKnight B (1997) Risk of endometrial cancer in relation to use of estrogen combined cyclic progestagen therapy in postmenopausal women. Lancet 349: 458-461.